Interstitial Lung Disease clinical trials at UCSD
1 in progress, 0 open to eligible people
Sorry, not currently recruiting here
Study RIN-PF-301 is designed to evaluate the superiority of inhaled treprostinil against placebo for the change in absolute forced vital capacity (FVC) from baseline to Week 52.
La Jolla, California and other locations
Our lead scientists for Interstitial Lung Disease research studies include Gordon Yung, MD.